Skip to main content
Signal8

DAVION HEALTHCARE PLC (DAVI)

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

Davion Healthcare Plc logo

Davion Healthcare Plc

NASDAQ:DAVIHealthcare
+0.98%$1.03
CLOSED
AH$1.04+0.97%vs close
Mkt Cap$25.75M
EV-
Float13.48M
O/S25M
VOL186K sh
$ Vol$192K
RVOL0.14×
Inst Own-
SI4.6%
Net Cash/Sh-
Dilution
Davion Healthcare Plc logoNASDAQ:DAVIClosed$1.03+0.98%
Historical Data
DateOpenHighLowCloseVolume
Nov 17, 20261.081.150.93651.03186,360
Nov 16, 20261.031.160.99011.02333,462
Nov 13, 20261.171.190.91401.00331,501
Nov 12, 20261.391.481.191.19204,672
Nov 11, 20261.541.561.321.39294,135
Nov 10, 20261.621.761.571.58163,404
Nov 9, 20261.631.801.501.75269,691
Nov 6, 20261.371.671.361.59423,767
Nov 5, 20261.591.631.311.31241,416
Nov 4, 20261.611.671.501.67189,847
Nov 3, 20261.431.611.401.54366,320
Nov 2, 20261.681.681.461.49429,501
Oct 30, 20262.242.241.651.681,401,826
Oct 29, 20263.133.202.592.694,176,095
Oct 28, 20263.723.812.953.298,533,316
Oct 27, 20263.723.992.783.006,069,899
Oct 26, 20264.864.913.914.07380,799
Oct 23, 20268.898.895.676.00479,471
Oct 22, 202612.2512.309.5211.65558,418
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
0.0%
Institutional
(0)
20.7%
Insiderⓘ
(1)
0.0%
5%+ Owners
(0)
79.3%
Unattributed (incl. retail)ⓘ
Insider20.7%
Unattributed (incl. retail)79.3%
Top Shareholders
Sources: Form 4O/S: 25.0M · as of 2 Sep 2026 · SEC filings
Insiders & Institutional Holders

Insiders

About

Davion Healthcare Plc is an Irish public limited company that develops and commercializes non-invasive home tests for the early detection of health anomalies, including cancers.

Its products use thermography: a liquid crystal film placed on the skin shows temperature differences as color shifts, and AI analysis of smartphone images interprets the result.

It has four completed tests, BreastCheck, FootFlow (diabetic circulation), Testic and ThermaDerm, all non-diagnostic Class I devices. BreastCheck and FootFlow have been FDA-registered, and registered in the EU and UK, since November 2023. Davion operates a licensing model and has a global manufacturing and distribution agreement for BreastCheck with NeuRX Health Inc., which provides $120 million in staged license fees and minimum annual royalties of $10 million over an initial ten-year term.

The company was incorporated in Cyprus in 2022 and re-domiciled to Ireland in 2024, keeping a wholly owned Cyprus subsidiary.

It plans to pair product commercialization with acquisitions of complementary healthcare businesses, and has launched a £30 million five-year senior secured bond through Davion Healthcare Finance Ltd. The listing is a direct listing of 25,000,000 existing ordinary shares, with no new capital raised.

Key Metrics
Market Cap$25.75M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership-

No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.

SectorHealthcare
IndustryMedical - Devices
ExchangeNASDAQ
CountryIEIE
IPO DateOct 22, 2026
Shares Outstanding25.00M
Authorized Shares
Float13.48M
52-Week Range
$0.9365$12.30
$1.03(1st percentile)
Volume
Average Daily Volume1.32M
186.36K today vs 1.32M avg(-86%)

30d Avg

1.32M

60d Avg

1.32M

90d Avg

1.32M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Signal8's dilution snapshot of DAVI as of Dec 31, 2025 records 1 outstanding warrant series and a PIPE closed Mar 10, 2026, from SEC filings. Davion Healthcare PLC (NASDAQ: DAVI) traded at $1.03 on Nov 17, 2026, up 0.98% from the previous close of $1.02. 52-week range: $0.9365 to $12.30. The company is in the Healthcare sector (Medical - Devices).